Biogen and its rivals

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Biogen and its rivals

Postby Needled » Fri Mar 27, 2009 5:36 am

This article describes a Phase III trial of a new formulation of Avonex taken every two or four weeks and comments on competition with Tysabri and some of the oral meds in trial. Looks like Cladribine and Fingolimod are still on track for FDA filing this year. Novartis releases its first quarter results on April 23, so there should be an update on Fingolimod then as well. ... ivals.html
User avatar
Family Elder
Posts: 361
Joined: Wed Jan 14, 2009 4:00 pm
Location: Connecticut


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service